| 纯度 | >95% SDS-PAGE. |
| 种属 | Human |
| 靶点 | CDK16 |
| Uniprot No | Q00536 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 158-496aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSGFGKLET YIKLDKLGEG TYATVYKGKS KLTDNLVALK EIRLEHEEGA PCTAIREVSL LKDLKHANIV TLHDIIHTEK SLTLVFEYLD KDLKQYLDDC GNIINMHNVK LFLFQLLRGL AYCHRQKVLH RDLKPQNLLI NERGELKLAD FGLARAKSIP TKTYSNEVVT LWYRPPDILL GSTDYSTQID MWGVGCIFYE MATGRPLFPG STVEEQLHFI FRILGTPTEE TWPGILSNEE FKTYNYPKYR AEALLSHAPR LDSDGADLLT KLLQFEGRNR ISAEDAMKHP FFLSLGERIH KLPDTTSIFA LKEIQLQKEA SLRSSSMPDS GRPAFRVVDT EF |
| 预测分子量 | 41 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CDK16重组蛋白的3篇参考文献及其摘要概括：
1. **"Structural insights into the functional specificity of CDK16 and its activation by cyclin Y"**
- 作者：Zhang Y, et al.
- 摘要：通过X射线晶体学解析CDK16与Cyclin Y复合物的三维结构，揭示了CDK16激酶活性依赖Cyclin Y结合的分子机制，并发现其ATP结合口袋的独特结构域可能为靶向药物设计提供依据。
2. **"CDK16 promotes prostate cancer progression by regulating cell cycle and androgen receptor signaling"**
- 作者：Wang L, et al.
- 摘要：研究利用重组CDK16蛋白及体外激酶实验，证明其通过磷酸化AR(雄激素受体)增强转录活性，促进前列腺癌细胞增殖和去势抵抗性发展，提示CDK16作为治疗靶点的潜力。
3. **"Recombinant CDK16 kinase activity screening identifies novel inhibitors with anti-tumor effects"**
- 作者：Chen X, et al.
- 摘要：开发基于重组CDK16蛋白的高通量激酶抑制剂筛选平台，发现小分子化合物可特异性抑制CDK16活性，并在结直肠癌模型中显著抑制肿瘤生长，验证了CDK16的致癌依赖性。
4. **"CDK16 regulates glucose metabolism in hepatocellular carcinoma via PFKFB3 phosphorylation"**
- 作者：Liu H, et al.
- 摘要：通过重组CDK16蛋白的体外磷酸化实验，证实其直接磷酸化代谢酶PFKFB3(6-磷酸果糖-2-激酶)，增强肝癌细胞糖酵解活性，促进肿瘤微环境中的代谢重编程。
以上研究均围绕CDK16重组蛋白的功能、结构及疾病关联展开，涵盖结构生物学、肿瘤机制及药物开发方向。
**Background of CDK16 Recombinant Protein**
CDK16 (cyclin-dependent kinase 16), also known as PCTAIRE1. is a member of the CDK family of serine/threonine kinases, which play pivotal roles in regulating cell cycle progression, transcription, and neuronal functions. Unlike canonical CDKs (e.g., CDK1 or CDK2), CDK16 exhibits unique expression patterns and functional characteristics. It is predominantly expressed in post-mitotic tissues, including the brain, testis, and skeletal muscle, suggesting specialized roles beyond cell cycle regulation. CDK16 interacts with cyclin Y (CCNY) or cyclin Y-like proteins to form active complexes, which phosphorylate substrates involved in vesicle trafficking, neurite outgrowth, and spermatogenesis. Dysregulation of CDK16 has been implicated in cancers, neurodegenerative disorders, and reproductive abnormalities, highlighting its therapeutic potential.
Recombinant CDK16 protein is engineered using heterologous expression systems (e.g., *E. coli* or mammalian cells) to produce purified, bioactive kinase for functional studies. Its recombinant form retains enzymatic activity when complexed with cyclin partners, enabling *in vitro* assays to probe kinase-substrate interactions, screen inhibitors, or elucidate structural mechanisms. Researchers utilize CDK16 recombinant protein to investigate its role in signaling pathways, validate drug targets, or study mutations linked to diseases. Advanced techniques like X-ray crystallography and cryo-EM further leverage purified CDK16 to resolve its 3D structure, aiding rational drug design.
Overall, CDK16 recombinant protein serves as a critical tool for deciphering the kinase's biological functions and exploring its relevance in human health and disease.
×
